Illumina has seen its stock price rise more than 12% following the acquisition of single-cell technology company, Fluent BioSciences, for an undisclosed amount.
Illumina’s overall stock price saw a sharp rise from $104 per share before the deal closure on 9 July, up to $118 per share after the company acquired Fluent BioSciences in a bid to gain access to its single-cell analysis technology which is designed to make the process more efficient.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Fluent’s latest version of its single-cell analysis device, PIPseq V, was released in May 2024, with the aim of cutting down the amount of time cell RNA Sequencing, a process that allows researchers to examine both known and novel features in a single assay. At the same time, the device is scalable, and capable of processing a range from 100 cells up to 1 million.
Speaking following the acquisition, Steven Barnard, chief technology officer of Illumina, said: “The addition of Fluent BioSciences to Illumina will provide significant and new capabilities to our customers in a key growth area and advances our multiomics growth strategy.
“Single-cell research opens doors to new areas of discovery, and Fluent’s innovative, accessible, and flexible single-cell method will accelerate our ability to deliver full multiomics solutions for our customers.”
Illumina plans to build on Fluent’s single-cell analysis technology. The acquisition follows after Illumina was forced to spin out Grail after objections from the European Union and US regulators leaving Illumina with only a 14.5% stake in the company.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataBarnard added: “Our goal is to continue to develop the sequencing eco-system and support the best multiomics solutions like single-cell analysis. We want customers to have the flexibility to adopt the tools that best fit their needs.” Elsewhere in the field of RNA sequencing, Boston-based Foundation Medicine has started the commercial launch of its RNA sequencing test FoundationOne RNA in the US.
